Bolt Biotherapeutics (BOLT)
(Delayed Data from NSDQ)
$0.73 USD
0.00 (0.00%)
Updated Jul 24, 2024 03:46 PM ET
After-Market: $0.74 +0.01 (1.36%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Bolt Biotherapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 8 | 6 | 1 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 8 | 6 | 1 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 84 | 96 | 94 | 49 | 31 |
Income After Depreciation & Amortization | -76 | -90 | -93 | -49 | -31 |
Non-Operating Income | 7 | 2 | -6 | -12 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -69 | -88 | -99 | -61 | -30 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -69 | -88 | -99 | -61 | -30 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -69 | -88 | -99 | -61 | -30 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -79 | -88 | -89 | -49 | -31 |
Depreciation & Amortization (Cash Flow) | -3 | 2 | 4 | 1 | 0 |
Income After Depreciation & Amortization | -76 | -90 | -93 | -49 | -31 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 37.81 | 37.36 | 33.20 | 2.10 | NA |
Diluted EPS Before Non-Recurring Items | -1.83 | -2.36 | -2.97 | -22.26 | NA |
Diluted Net EPS (GAAP) | -1.83 | -2.36 | -2.97 | -28.89 | NA |
Fiscal Year end for Bolt Biotherapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 5.27 | 2.09 | 2.53 | 1.43 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 5.27 | 2.09 | 2.53 | 1.43 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 22.37 | 21.85 | 20.71 | 21.26 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -17.10 | -19.76 | -18.18 | -19.83 |
Non-Operating Income | NA | 6.28 | 1.86 | 1.93 | 1.78 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -10.81 | -17.90 | -16.26 | -18.06 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -10.81 | -17.90 | -16.26 | -18.06 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -10.81 | -17.90 | -16.26 | -18.06 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 38.07 | 37.94 | 37.87 | 37.75 |
Diluted EPS Before Non-Recurring Items | NA | -0.28 | -0.47 | -0.43 | -0.48 |
Diluted Net EPS (GAAP) | NA | -0.28 | -0.47 | -0.43 | -0.48 |